DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q2 2020

SEC EDGAR SourceSEC Filings

Top Holdings371 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
BABABABA
ADR

ALIBABA GROUP HOLDING-SP ADR

1.4M$305.9M7.4%$182.58+11.84%
6 qtrssince 2019-Q1
Increased
74
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

4.2M$238.9M5.8%$38.02+35.10%
6 qtrssince 2019-Q1
Increased
63

CYTOKINETICS INC

3.1M$73.3M1.8%$11.72+101.32%
5 qtrssince 2019-Q2
Increased
49
JDJD
ADR

JD.COM INC-ADR

990,649$59.6M1.4%$36.65+47.50%
2 qtrssince 2020-Q1
Decreased
0
HDBHDB
ADR

HDFC BANK LTD-ADR

1.3M$57.1M1.4%$25.82-17.92%
6 qtrssince 2019-Q1
Decreased
0
IBNIBN
ADR

ICICI BANK LTD-SPON ADR

5.8M$53.8M1.3%$10.72-16.24%
6 qtrssince 2019-Q1
Decreased
0
MYOKMYOKDelisted

MYOKARDIA INC

552,100$53.3M1.3%
6 qtrssince 2019-Q1
Decreased
0
SESE
ADR

SEA LTD-ADR

447,586$48M1.2%$38.36+183.56%
6 qtrssince 2019-Q1
Decreased
0

NVIDIA CORP

122,533$46.6M1.1%$6.60+38.94%
3 qtrssince 2019-Q4
Decreased
0

NEBIUS GROUP NV

919,502$46M1.1%
6 qtrssince 2019-Q1
Decreased
0

META PLATFORMS INC-CLASS A

194,083$44.1M1.1%$218.61+0.23%
6 qtrssince 2019-Q1
Increased
74

ANALOG DEVICES INC

353,352$43.3M1.1%$108.010.00%
1 qtr
New
67
SWTXSWTXDelisted

SPRINGWORKS THERAPEUTICS INC

1M$42.3M1.0%
4 qtrssince 2019-Q3
Increased
59
DAVADAVA
ADR

ENDAVA PLC

848,406$41M1.0%$34.37+40.86%
6 qtrssince 2019-Q1
Decreased
0

NATERA INC

780,371$38.9M0.9%$28.80+65.63%
5 qtrssince 2019-Q2
Increased
42

Palomar Holdings, Inc.

434,575$37.3M0.9%$39.56+107.19%
5 qtrssince 2019-Q2
Decreased
0
ARGXARGX
ADR

ARGENX SE - ADR

164,028$36.9M0.9%$125.14+78.43%
6 qtrssince 2019-Q1
Decreased
0

TANDEM DIABETES CARE INC

361,605$35.8M0.9%$66.72+31.61%
6 qtrssince 2019-Q1
Increased
43

SITIME CORP

748,383$35.5M0.9%$31.55+41.94%
3 qtrssince 2019-Q4
Increased
58
IEMGIEMG
ETF

ISHARES CORE MSCI EMERGING

716,829$34.1M0.8%$41.60-1.63%
5 qtrssince 2019-Q2
Increased
56
$4.1B
AUM
371
Positions
Q2 2020
Filing
Rating · 2.0
Quarterly Portfolio Change
+20%Q2'19$3.2B-4%Q3'19$3.1B+22%Q4'19$3.8B-20%Q1'20$3B+37%Q2'20$4.1B
Activity profile
$ moved · Q2'20
New29%Increased36%Decreased15%Exited20%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.0 quarters
<1Q21%1-4Q32%1-2Y45%2Y+2%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $4.1B across 371 positions as of Q2 2020. Top holdings: BABA (7.4%), TSM (5.8%), CYTK (1.8%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q2 2020 Summary

Active quarter - 126 new positions, 151 exits, 133 increased. Top move: BABA (INCREASED, conviction 74). Portfolio: $4.1B across 371 positions.

Top holdings by portfolio weight

Total AUM$4B
BABA7.44%
TSM5.81%
CYTK1.78%
JD1.45%
HDB1.39%
IBN1.31%
MYOK1.30%
SE1.17%
NVDA1.13%
NBIS1.12%
Other1.07%

Portfolio allocation by GICS sector

Sectors11
Consumer Cyclical21.19%
Technology19.83%
Unknown19.18%
Healthcare15.65%
Financial Services7.33%
Communication Services5.96%
Industrials5.24%
Consumer Defensive3.45%
Basic Materials1.85%
Real Estate0.24%
Other0.10%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Consumer Cyclical, Technology, Unknown
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record66
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used